Kucukdumlu Asligul, Tuncbilek Meral, Bilget Guven Ebru, Cetin Atalay Rengul
Acta Chim Slov. 2017 Sep;64(3):621-632. doi: 10.17344/acsi.2017.3419.
A series of 6-(4-substituted phenyl)-9-(tetrahydropyran-2-yl)purines 3-9, 6-(4-substituted phenyl)purines 10-16, 9-((4-substituted phenyl)sulfonyl)-6-(4-substituted phenyl)purines 17-32 were prepared and screened initially for their in vitro anticancer activity against selected human cancer cells (liver Huh7, colon HCT116, breast MCF7). 6-(4-Phenoxyphenyl) purine analogues 9, 16, 30-32, had potent cytotoxic activities. The most active purine derivatives 5-9, 14, 16, 18, 28-32 were further screened for their cytotoxic activity in hepatocellular cancer cells. 6-(4-Phenoxyphenyl)-9-(tetrahydropyran-2-yl)-9H-purine (9) had better cytotoxic activity (IC50 5.4 μM) than the well-known nucleobase analogue 5-FU and known nucleoside drug fludarabine on Huh7 cells. The structure-activity relationship studies reported that the substitution at C-6 positions in purine nucleus with the 4-phenoxyphenyl group is responsible for the anti-cancer activity.
制备了一系列6-(4-取代苯基)-9-(四氢吡喃-2-基)嘌呤3-9、6-(4-取代苯基)嘌呤10-16、9-((4-取代苯基)磺酰基)-6-(4-取代苯基)嘌呤17-32,并初步筛选了它们对选定人类癌细胞(肝癌Huh7、结肠癌HCT116、乳腺癌MCF7)的体外抗癌活性。6-(4-苯氧基苯基)嘌呤类似物9、16、30-32具有较强的细胞毒活性。对活性最强的嘌呤衍生物5-9、14、16、18、28-32进一步筛选其在肝癌细胞中的细胞毒活性。6-(4-苯氧基苯基)-9-(四氢吡喃-2-基)-9H-嘌呤(9)对Huh7细胞的细胞毒活性(IC50为5.4 μM)优于著名的核碱基类似物5-氟尿嘧啶和已知的核苷药物氟达拉滨。构效关系研究表明,嘌呤核C-6位被4-苯氧基苯基取代是其抗癌活性的原因。